S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Forecast, Price & News

$104.53
+0.46 (+0.44%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$99.82
$105.82
50-Day Range
$93.97
$143.33
52-Week Range
$92.26
$161.98
Volume
173,125 shs
Average Volume
288,500 shs
Market Capitalization
$3.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
30 days | 90 days | 365 days | Advanced Chart
Receive KRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Karuna Therapeutics logo

About Karuna Therapeutics

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Headlines

What 4 Analyst Ratings Have To Say About Karuna Therapeutics
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
118
Year Founded
N/A

Sales & Book Value

Annual Sales
$36.96 million
Book Value
$15.18 per share

Profitability

Net Income
$-143.80 million
Pretax Margin
-464.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,474,000
Market Cap
$3.12 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/22/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.52 out of 5 stars

Medical Sector

121st out of 1,416 stocks

Pharmaceutical Preparations Industry

47th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -













Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

Is Karuna Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics
or view top-rated stocks.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Karuna Therapeutics
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.95) EPS for the quarter, topping analysts' consensus estimates of ($2.10) by $0.15. During the same period in the previous year, the business posted ($1.10) earnings per share.
View Karuna Therapeutics' earnings history
.

What price target have analysts set for KRTX?

9 analysts have issued 12 month price objectives for Karuna Therapeutics' stock. Their forecasts range from $152.00 to $190.00. On average, they expect Karuna Therapeutics' stock price to reach $176.22 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for Karuna Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Karuna Therapeutics' key executives?
Karuna Therapeutics' management team includes the following people:
What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.10%), BlackRock Inc. (5.44%), State Street Corp (3.44%), Viking Global Investors LP (3.26%), Wellington Management Group LLP (2.86%) and Rock Springs Capital Management LP (1.45%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics
.

Which major investors are selling Karuna Therapeutics stock?

KRTX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Farallon Capital Management LLC, First Light Asset Management LLC, Wellington Management Group LLP, Citigroup Inc., Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, and Eagle Asset Management Inc.. Company insiders that have sold Karuna Therapeutics company stock in the last year include Andrew Craig Miller, Atul Pande, Laurie J Olson, Stephen K Brannan, and Troy A Ignelzi.
View insider buying and selling activity for Karuna Therapeutics
or view top insider-selling stocks.

Which major investors are buying Karuna Therapeutics stock?

KRTX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Lord Abbett & CO. LLC, Bank of New York Mellon Corp, Viking Global Investors LP, Jennison Associates LLC, Victory Capital Management Inc., Woodline Partners LP, and Ghost Tree Capital LLC. Company insiders that have bought Karuna Therapeutics stock in the last two years include Heather Preston, James Healy, and Steven M Paul.
View insider buying and selling activity for Karuna Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $104.53.

How much money does Karuna Therapeutics make?

Karuna Therapeutics has a market capitalization of $3.12 billion and generates $36.96 million in revenue each year. The company earns $-143.80 million in net income (profit) each year or ($5.780010) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

Karuna Therapeutics employs 118 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at (857) 449-2244 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.